IP Library Granted Patent US 9,487,564
Granted Patent B2
US 9,487,564 · App. 12/108,920 · Granted Nov 8, 2016

Patent

Inventors: Darren E. Straub (New London, MN); Daryll A. Emery (New London, MN)
Assignee: EPITOPIX, LLC
C07K14/195A61K38/00A61K39/00A61K39/39A61K2039/505C12N1/20C12R1/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,564
App. No.
12/108,920
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Claims (7)

1. A composition comprising an isolated whole cell preparation of a Fusobacterium spp., wherein the cells comprise at least two meta regulated polypeptides having molecular weights between 76 kDa and 86kDa, between 62 kDa and 68 kDa, between 45 kDa and 53 kDa, between 34 kDa and 43 kDa, or between 24 kDa and 35 kDa, wherein molecular weight is determined by eiectrophoresis on a sodium dodecyl sulfate-polyacrylamide gel, wherein the metal regulated polypeptides are natively expressed by a Fusobacterium spp. when incubated in medium that includes a metal chelator and not natively expressed at a detectable level when grown in the medium in the absence of a metal chelator and further comprising an adjuvant.

2. The composition of claim 1 wherein the Fusobacterium spp. is F. necrophorum or F. nucleatum.

3. The composition of claim 1 wherein the Fusobacterium spp. is the F. necrophorum strain deposited with the American Type Culture Collection (ATCC) and given ATCC Accession No. PTA-10318.

4. The composition of claim 1 wherein the composition does not comprise a polypeptide having leukotoxin activity.

5. The composition of claim 1 wherein each of the at least two metal regulated polypeptides has a molecular weight between 78 kDa and 84 kDa, between 64kDa and 66 kDa, between 47 kDa and 51 kDa, between 36 kDa and 41kDa, or between 27 kDa and 32 kDa.

6. The composition of claim 1 wherein each of the at least two metal regulated polypeptides has a molecular weight of 83 kDa, 79 kDa, 65 kDa, 49 kDa, 39kDa, 31 kDa, or 28 kDa.

7. The composition of claim 1 wherein the cells further comprise at least one polypeptide having a molecular weight of between 136 kDa and 144 kDa, between 69 kDa and 77 kDa, between 39 kDa and 47 kDa, or between 29 kDa and 37 kDa, and natively expressed by a Fusobacterium spp. when grown in medium with or without a metal chelator, wherein expression of the polypeptide is enhanced during growth in the medium with the metal chelator.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2016
From: STRAUB, DARREN E.; EMERY, DARYLL A.
To: EPITOPIX, LLC
Reel/Frame 040401/0153 →
SECURITY AGREEMENT Recorded Feb 19, 2010
From: WP HOLDING, INC.; WLSI HOLDING, INC.; LIFE-SCIENCE INNOVATIONS, LLC; EPITOPIX, LLC
To: UNITED FCS, PCA
Reel/Frame 023957/0977 →
Continuity (3)
Division 11212115 · Aug 25, 2005
Provisional Application 60604349 · Aug 25, 2004
Related Publication 20080199941A1 · Aug 21, 2008